WEST Search History

Hide Items | Restore | Clear | Cancel

updated 1st 3/8/07

DATE: Monday, August 08, 2005

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
☐	L1	(pressure near5 (ulcers or ulcer or bedsore or bed-sore or decubiti or decubitius or decubitis or sore)).clm.	168
☐	L2	(bedsore or bed-sore or decubiti or decubitius or decubitis or pressure-sore).clm.	115
☐	L3	(L2 or l1)	268
☐	L4	(botox or btx or bont or botulin or botinolysin or botulinum or neurotoxin or toxin or btxa or bonta or type-a or typea).clm.	5773
☐	L5	L4 and l3	3
☐	L6	L4 and l3	3
☐	L7	(botox or btx or bont or botulin or botinolysin or botulinum or neurotoxin or toxin or btxa or bonta or type-a or typea)	62009
☐	L8	(botox or btx or bont or botulin or botinolysin or botulinum or neurotoxin or btxa or bonta or type-a or typea)	13360
☐	L9	(botox or btx or bont or botulin or botinolysin or botulinum or neurotoxin or btxa or bonta or type-a or typea or botulinolysin)	13364
☐	L10	(bedsore or bed-sore or decubiti or decubitius or decubitis or pressure-sore)	3001
☐	L11	(pressure near5 (ulcers or ulcer or bedsore or bed-sore or decubiti or decubitius or decubitis or sore))	4241
☐	L12	(L11 or l10) same (l8 or l9)	3
☐	L13	(wound or sore).ti,ab,clm. same (l8 or l9).ti,ab,clm.	16
☐	L14	L13 not l12	16

END OF SEARCH HISTORY

20020192239. 08 Jan 02. 19 Dec 02. Use of botulinum toxin for the treatment of chronic facial pain. Borodic, Gary E., et al. 424/247.1; A61K039/08.

☐ 2. 20020151056. 16 May 01. 17 Oct 02. Novel differentiation inducing process of embryonic stem cell to ectodermal cell and its use. Sasai, Yoshiki, et al. 435/368; C12N005/08.

☐ 3. 6869610. 18 Jul 02; 22 Mar 05. Pain treatment by peripheral administration of a neurotoxin. Aoki; Kei Roger, et al. 424/239.1; 424/236.1 424/9.1 435/252.7 514/12 514/2 530/350. A61K03908 A61K03902.

☐ 4. 6447787. 18 Apr 01; 10 Sep 02. Methods for enhancing wound healing. Gassner; Holger G., et al. 424/247.1; 424/236.1 424/239.1. A61K039/08 A61K039/02.

☐ 5. DE003306383A1. 24 Feb 83. 30 Aug 84. Cavity-forming wound dressing for the ambulant treatment of the wound space climate dressing. SCHELOWSKY, MICHAEL. 128/888. A61F013/00; A61L015/03 A61N001/20 A61N001/04.

☐ 6. WO2005032480A. Method of delivering oxygen to blood and tissue in treatment of e.g. cancer, viral diseases, ocular diseases and inflammatory diseases, involves delivery source comprising aqueous solution of tetrameric oxygen. BOSTON, J. A61K000/00.

☐ 7. US20030027158A. New nucleic acid sequence encoding a human breast tumor-associated protein 47-like polypeptide, useful for treating cardiovascular disorders, neural disorders, diabetes mellitus and cancers. FERNANDES, E, et al. C07H021/04 C12N005/06 C12P021/02 C12Q001/68 G01N033/574.

☐ 8. US20020192239A. Treating pain caused by neuralgia e.g. facial pain or post-operative incisional wound pain e.g. pain associated with cancer treatment, by administering botulinum toxin to afflicted area of patient. ACQUADRO, M A, et al. A61K039/08.

☐ 9. WO 200232447A. Pharmaceutical composition for manufacture of cell damage inhibitor and for neurodegenerative diseases, ischemic neuropathies or inhibiting cell damage e.g. neuronal damage, comprises FR901459 substance or its salt. HINO, M, et al. A61K038/00 A61K038/12 A61K038/13 A61P001/16 A61P003/00 A61P007/06 A61P009/10 A61P009/12 A61P009/14 A61P011/16 A61P013/12 A61P017/02 A61P017/14 A61P021/02 A61P025/00 A61P025/02 A61P025/08 A61P025/14 A61P025/16 A61P025/28 A61P027/00 A61P031/14 A61P031/18 A61P031/20 A61P031/22 A61P037/06 A61P039/02 A61P041/00 A61P043/00.

☐ 10. US 6447787B. Treating wounds especially facial wounds comprises administration of chemodenervating agent. GASSNER, H G, et al. A61K031/137 A61K031/167 A61K031/445 A61K031/519 A61K038/00 A61K039/02 A61K039/08 A61K045/00 A61P017/02.

☐ 11. WO 200006731A. Novel protein designated persephin-ARF, used for treating, e.g. amyotrophic lateral sclerosis and Alzheimer's disease. DE SAUVAGE, F, et al. C07K014/475 C07K016/22 C12N015/11 C12N015/12 C12Q001/68 G01N033/53.

☐ 12. US 6399078B. Use of compositions containing a receptor ligand and a receptor ligand binding molecule for treating e.g. infections, inflammatory or immune disease or disorder or cancers. BURNS, J M, et al. A61K031/727 A61K038/00 A61K038/17 A61K038/19 A61K039/00 A61K045/00 A61K047/00.

☐ 13. WO 9946381A. New polynucleotide encoding a fibroblast growth factor, useful for treating peripheral neuropathy, Alzheimer's disease, ischemic stroke, brain or spinal cord injury, nervous system tumors, multiple sclerosis or epilepsy. CEN, H, et al. A61K031/70 A61K031/711 A61K035/12 A61K038/18 A61K038/22 A61K048/00 A61P025/00 A61P025/14 A61P025/16 A61P025/28 C07H021/04 C07K014/50 C07K016/22 C12N001/18 C12N001/19 C12N001/21 C12N005/06 C12N005/10 C12N015/09 C12N015/12 C12P021/02 C12Q001/68 G01N033/68.

☐ 14. US 6030974A. Producing local anaesthesia in epithelial tissue region - by administration of long acting sodium channel blocking compound. FIELDS, H L, et al. A61K031/00 A61K031/505 B62M007/12 B62M023/02.

☐ 15. US 5989857A. Production of inactivated bioactive poly:peptide(s), particularly neuro:toxin(s) - by expression of DNA encoding the polypeptide in such a way that one or more di:sulphide bridges are not formed. MUNDSCHENK, D D, et al. A61K038/16 A61K038/17 A61K038/48 C07H021/04 C07K014/435 C07K014/46 C12N005/06 C12N009/00 C12N009/64 C12N009/99 C12N015/81 C12P021/02 C12P021/06.

☐ 16. EP 715977A. Pneumatic radial tyre for passenger car having reduced rolling resistance and improved steering stability - has stiffener above bead core between the carcass ply and its turn up portion and a rubber chafer outside the turn-up portion as well as a sidewall-reinforcing rubber layer. IDE, K. B60C009/00 B60C009/08 B60C009/14 B60C013/00 B60C015/00 B60C015/06.

Generate Collection | Print

Term	Documents
(13 NOT 12).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	16
(L13 NOT L12).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	16

Prev Page Next Page Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L14: Entry 6 of 16 File: DWPI Apr 14, 2005

DERWENT-ACC-NO: 2005-315319
DERWENT-WEEK: 200532

TITLE: Method of delivering oxygen to blood and tissue in treatment of e.g. cancer, viral diseases, ocular diseases and inflammatory diseases, involves delivery source comprising aqueous solution of tetrameric oxygen

Basic Abstract Text (5):
ADVANTAGE - The delivery source is readily available and adaptable. It is nontoxic having numerous application. The method improves blood oxygen level in chronic disease condition and anemia, thus reducing or eliminating the need for blood transfusion and the occurrences of transfusion associated reactions and blood borne infections. Use of the delivery source is superior to hyperbaric oxygen because of reduction in systemic side effects, localized treatment creating greater patient access and compliance. The aqueous solution of tetrameric oxygen includes many type of formulations, constitutions and delivery systems. It improves the effectiveness of treatment, improves treatment profiles and reduces issues such as side effects and limited accessibility. The method relieves tumor resistance by creating a localized hyperbaric condition, increases chemotherapy sensitivity and radiosensitivity of tumors; heals and prevents infection after surgical procedures including laser, plastic surgery, post Botox injection; facilitates drug mechanisms of existing drugs and wound healing, skin grafts and flaps; and is used in gene therapy when the hypoxic induction factor (HIF) pathway is a target where the target tissue is arteriosclerosis and atherosclerotic plaques.

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L14: Entry 9 of 16 File: DWPI Jun 17, 2004

DERWENT-ACC-NO: 2002-507921
DERWENT-WEEK: 200440

TITLE: Pharmaceutical composition for manufacture of cell damage inhibitor and for neurodegenerative diseases, ischemic neuropathies or inhibiting cell damage e.g. neuronal damage, comprises FR901459 substance or its salt

Basic Abstract Text (9):
The FR901459 substance or its salt is used for the production of drugs useful in treating wounds (bites, closed brain injury, increased intracranial masses and intracranial hypertension, surgical wound), physiological abnormalities (in electrolytes, glucose, vitamins, metabolism, homeostasis, etc), poisoning (metabolic poisons, toxins, neurotoxins), exposure to radiation (acute and delayed effects), vasospasms, etc.; for the treatment of various diseases secondary to, or delayed manifestations of, e.g. diseases accompanied by neuropathy of specific systems such as those related to vision, audition, vestibular function, olfaction, etc.; diseases of the brain inclusive of the brain stem and spinal cell tissues or the peripheral nervous system and certain specific diseases (myelitis, myelopathy), etc.; neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, etc.); infections (herpes virus infection, AIDS associated with cellular sequelae, AIDS myelopathy, etc.; senescence; ischemic neuropathies associated with cerebral thrombosis, cerebral embolism or cerebral hemorrhage: respiratory systemic hypoxia (hypoxic brain in anesthesia; anemia; functional insufficiency of erythrocytes and hemoglobins); hypertension; ischemic liver diseases (cirrhosis etc.); type B or C hepatitis; disturbance of renal blood flow; neuropathies associated with epilepsy or convulsions; and myocardial hypertrophy; or as a liver regeneration promoter; a tissue protectant for the protection of the liver transplant or the prevention of tissue diseases accompanied by cell death; an additive for the preservation of organ grafts; a trichogenic agent; an inhibitor of neurotransmitters; a memory modulating agent etc.; and for securing a protective effect on cellular tissues and cell functions before, during, or after occurrence of cell damage.

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L14: Entry 10 of 16 File: DWPI May 1, 2002

DERWENT-ACC-NO: 2000-350590
DERWENT-WEEK: 200368

TITLE: Treating wounds especially facial wounds comprises administration of chemodenervating agent

INVENTOR: GASSNER, H G; SHERRIS, D A

PATENT-ASSIGNEE: MAYO FOUND MEDICAL EDUCATION & RES (MAYON), MAYO FOUND MEDICAL EDUCATION RES (MAYON), MAYO FOUND MEDICAL EDUCATIONAL RES (MAYON), GASSNER H G (GASSI), SHERRIS D A (SHERI)

PRIORITY-DATA: 1998US-105688P (October 27, 1998), 2001US-0807793 (April 18, 2001), 2001US-0995022 (November 26, 2001)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
MX 2001004254 A1	May 1, 2002		000	A61K038/00
WO 200024419 A1	May 4, 2000	E	022	A61K039/08
AU 200017064 A	May 15, 2000		000	
BR 9914891 A	July 17, 2001		000	A61K039/08
EP 1128844 A1	September 5, 2001	E	000	A61K039/08
CN 1324246 A	November 28, 2001		000	A61K039/08
KR 2001089347 A	October 6, 2001		000	A61K039/08
US 6447787 B1	September 10, 2002		000	A61K039/08
JP 2002528421 W	September 3, 2002		020	A61K045/00
US 20030036502 A1	February 20, 2003		000	A61K039/08

DESIGNATED-STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
MX2001004254A1	October 15, 1999	1999WO-US24182	
MX2001004254A1	April 27, 2001	2001MX-0004254	

MX2001004254A1		WO 200024419	Based on
WO 200024419A1	October 15, 1999	1999WO-US24182	
AU 200017064A	October 15, 1999	2000AU-0017064	
AU 200017064A		WO 200024419	Based on
BR 9914891A	October 15, 1999	1999BR-0014891	
BR 9914891A	October 15, 1999	1999WO-US24182	
BR 9914891A		WO 200024419	Based on
EP 1128844A1	October 15, 1999	1999EP-0960130	
EP 1128844A1	October 15, 1999	1999WO-US24182	
EP 1128844A1		WO 200024419	Based on
CN 1324246A	October 15, 1999	1999CN-0812622	
KR2001089347A	April 25, 2001	2001KR-0705176	
US 6447787B1	October 27, 1998	1998US-105688P	Provisional
US 6447787B1	October 15, 1999	1999WO-US24182	
US 6447787B1	April 18, 2001	2001US-0807793	
US 6447787B1		WO 200024419	Based on
JP2002528421W	October 15, 1999	1999WO-US24182	
JP2002528421W	October 15, 1999	2000JP-0578027	
JP2002528421W		WO 200024419	Based on
US20030036502A1	October 27, 1998	1998US-105688P	Provisional
US20030036502A1	October 15, 1999	1999WO-US24182	Div ex
US20030036502A1	April 18, 2001	2001US-0807793	Div ex
US20030036502A1	November 26, 2001	2001US-0995022	

INT-CL (IPC): A61 K 31/137; A61 K 31/167; A61 K 31/445; A61 K 31/519; A61 K 38/00; A61 K 39/02; A61 K 39/08; A61 K 45/00 ; A61 P 17/02

ABSTRACTED-PUB-NO: US 6447787B
BASIC-ABSTRACT:

NOVELTY - Treating a patient having a wound comprises local administration of a chemodenervating agent such that heating of the wound is enhanced.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(A) a composition comprising a chemodenervating agent, a local anaesthetic agent and a vasoconstrictive agent;

(B) an article of manufacture comprising packaging material and a chemodenervating agent, in which the packaging material comprises a label that indicates the chemodenervating agent is useful for treating a patient having a wound, and in which local administration of the chemodenervating agent enhances healing of the wound.

ACTIVITY - Vulnerary.

A male patient (26 years of age) underwent scar revision excision surgery. The scar was a result of a trauma at age 7, and was closed at a tertiary referral center at the time. The patient was placed in a supine position and 5 ml of 0.5% lidocaine with 1:200000 epinephrine was locally injected. Botulinum toxin A was injected (10 units) into the frontalis muscle under direct vision fanning out from the wound. An additional 7.5 units of botulinum toxin A were injected into the procerus and

corrugator muscles bilaterally, as frowning caused distortion of the wound. The wound healed well in the early post-operative period. Compared to the pre-operative scar, the cosmetic appearance of the resulting scar 12 months past operatively was excellent and superior to the initial scar.

MECHANISM OF ACTION - Vasoconstrictor.

USE - The method can be used for enhancing wound healing especially facial wounds (claimed).

ADVANTAGE - The new therapy includes injection of a chemodenervating agent to paralyze muscles capable of exerting tension on such wounds, providing better wound healing with minimal scar development. In addition, early immobilization in elective procedures also allows a surgeon to use finer sutures, further improving the cosmetic result.

ABSTRACTED-PUB-NO: WO 200024419A
EQUIVALENT-ABSTRACTS:

NOVELTY - Treating a patient having a wound comprises local administration of a chemodenervating agent such that heating of the wound is enhanced.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(A) a composition comprising a chemodenervating agent, a local anaesthetic agent and a vasoconstrictive agent;

(B) an article of manufacture comprising packaging material and a chemodenervating agent, in which the packaging material comprises a label that indicates the chemodenervating agent is useful for treating a patient having a wound, and in which local administration of the chemodenervating agent enhances healing of the wound.

ACTIVITY - Vulnerary.

A male patient (26 years of age) underwent scar revision excision surgery. The scar was a result of a trauma at age 7, and was closed at a tertiary referral center at the time. The patient was placed in a supine position and 5 ml of 0.5% lidocaine with 1:200000 epinephrine was locally injected. Botulinum toxin A was injected (10 units) into the frontalis muscle under direct vision fanning out from the wound. An additional 7.5 units of botulinum toxin A were injected into the procerus and corrugator muscles bilaterally, as frowning caused distortion of the wound. The wound healed well in the early post-operative period. Compared to the pre-operative scar, the cosmetic appearance of the resulting scar 12 months past operatively was excellent and superior to the initial scar.

MECHANISM OF ACTION - Vasoconstrictor.

USE - The method can be used for enhancing wound healing especially facial wounds (claimed).

ADVANTAGE - The new therapy includes injection of a chemodenervating agent to paralyze muscles capable of exerting tension on such wounds, providing better wound healing with minimal scar development. In addition, early immobilization in elective procedures also allows a surgeon to use finer sutures, further improving the cosmetic result.

CHOSEN-DRAWING: Dwg.1/1

DERWENT-CLASS: B05
CPI-CODES: B04-D02; B04-F10B; B06-D17; B06-E05; B14-C08; B14-F02C; B14-J05; B14-N17B;

Previous Doc Next Doc Go to Doc#

L14: Entry 12 of 16 File: DWPI Dec 9, 1999

DERWENT-ACC-NO: 2000-105663
DERWENT-WEEK: 200242

TITLE: Use of compositions containing a receptor ligand and a receptor ligand binding molecule for treating e.g. infections, inflammatory or immune disease or disorder or cancers

Basic Abstract Text (8):
USE - The methods can be used for treating an infectious disease caused by a virus e.g. HIV, Epstein-Barr virus, rhinovirus, poliovirus, rabies virus, reovirus, influenza virus, herpes simplex virus, hepatitis virus, togavirus, varicella-zoster virus, paramyxovirus, cytomegalovirus, subacute sclerosing panencephalitis virus, adenovirus, poxvirus, reovirus, papovavirus, papillmavirus, polyomavirus, slow virus, or bacteria, e.g. Helicobacter pylori, Borelia burgdoferi, Legionella pneumophilia, Mycobacterium tuberculosis, M. avium M. intracellulare, M. kansaii, M. gordonae, M. leprae, Staphylococcus aureus, Neisseria gonorrhoeae, N. meningitidis, Listeria monocytogenes, S. pyogenes, S. agalactiae, S. faecalis, S. bovis, S. anginosus, S. pneumoniae, pathogenic Campylobacter species, pathogenic Enterococc us species, Harmophilus influenzae, Bacillus antracis, Corynebacterium diphtheriae, Enterobacter aerogenes, Klebsiella pneumoniae, pasturella multocide, pathogenic Bacteroides fragilis group species, Fusobacterium nucleatum, Streptobacillus moniliformis, treponema pallidium, Treponema pertenue, Leptospira, and Actimomyces isrealli, fungi, e.g. Cryptocossuc neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatidis, Chlamydia trachomatis, and Candida albicans, or a microbe, e.g. Bacillus anthracis, a pathogenic Bordetella species, Bordetella pertussis, Clostridium botulinum, C. tetani, Vibrio cholerae, Corynebactreium diphtheriae, E. coli, Pseudomonase aeruginosa, and Shigella dysenteriae (claimed). They can also be used for treating an inflammatory or an immune disease or disorder (e.g. AIDS) or cancer (claimed). In particular, they can be used for treating e.g. systemic lupus erythematosus, glomerulonephritis, vasculitis, pyogenic infections, immune complex disease, adult respiratory distress syndrome, septic shock or multiple organ failure, vascular diseases or disorders, cardiac disorders, cardiovascular system diseases and disorders, wound healing, limb regeneration, periodontal regeneration, neurological damage or diseases, e.g., Alzheimer's disease, Parkinson's disease, AIDS-related complex, cerebral palsy, depression or neuroendocrine disorders such as hyperthyroidism or hypertension, other diseases, conditions or disorders which result from aberrations or alterations of cell receptor-dependent processes including collateral growth and remodeling of cardiac blood vessels, angiogenesis, cellular transformation through autocrine or paracrine mechanisms, chemotactic stimulation of cells (e.g. endothelial), neurite outgrowth of neuronal precursor cell types (e.g. PC12 phaeochromoctoma). They can also be used for treating e.g. insulin-dependent hypoglycemic condition or amyloid diseases ad to promote skeletal muscle development thereby increasing muscle mass in livestock and obviating the need for excessive use of antibiotics and hormones to improve feed conversion and weight gain in animals. The methods can also be used in drug screening.

Equivalent Abstract Text (8):
USE - The methods can be used for treating an infectious disease caused by a virus

e.g. HIV, Epstein-Barr virus, rhinovirus, poliovirus, rabies virus, reovirus, influenza virus, herpes simplex virus, hepatitis virus, togavirus, varicella-zoster virus, paramyxovirus, cytomegalovirus, subacute sclerosing panencephalitis virus, adenovirus, poxvirus, reovirus, papovavirus, papillmavirus, polyomavirus, slow virus, or bacteria, e.g. Helicobacter pylori, Borelia burgdoferi, Legionella pneumophilia, Mycobacterium tuberculosis, M. avium M. intracellulare, M. kansaii, M. gordonae, M. leprae, Staphylococcus aureus, Neisseria gonorrhoeae, N. meningitidis, Listeria monocytogenes, S. pyogenes, S. agalactiae, S. faecalis, S. bovis, S. anginosus, S. pneumoniae, pathogenic Campylobacter species, pathogenic Enterococc us species, Harmophilus influenzae, Bacillus antracis, Corynebacterium diphtheriae, Enterobacter aerogenes, Klebsiella pneumoniae, pasturella multocide, pathogenic Bacteroides fragilis group species, Fusobacterium nucleatum, Streptobacillus moniliformis, treponema pallidium, Treponema pertenue, Leptospira, and Actimomyces isrealli, fungi, e.g. Cryptocossuc neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatidis, Chlamydia trachomatis, and Candida albicans, or a microbe, e.g. Bacillus anthracis, a pathogenic Bordetella species, Bordetella pertussis, Clostridium botulinum, C. tetani, Vibrio cholerae, Corynebactreium diphtheriae, E. coli, Pseudomonase aeruginosa, and Shigella dysenteriae (claimed). They can also be used for treating an inflammatory or an immune disease or disorder (e.g. AIDS) or cancer (claimed). In particular, they can be used for treating e.g. systemic lupus erythematosus, glomerulonephritis, vasculitis, pyogenic infections, immune complex disease, adult respiratory distress syndrome, septic shock or multiple organ failure, vascular diseases or disorders, cardiac disorders, cardiovascular system diseases and disorders, wound healing, limb regeneration, periodontal regeneration, neurological damage or diseases, e.g., Alzheimer's disease, Parkinson's disease, AIDS-related complex, cerebral palsy, depression or neuroendocrine disorders such as hyperthyroidism or hypertension, other diseases, conditions or disorders which result from aberrations or alterations of cell receptor-dependent processes including collateral growth and remodeling of cardiac blood vessels, angiogenesis, cellular transformation through autocrine or paracrine mechanisms, chemotactic stimulation of cells (e.g. endothelial), neurite outgrowth of neuronal precursor cell types (e.g. PC12 phaeochromoctoma). They can also be used for treating e.g. insulin-dependent hypoglycemic condition or amyloid diseases ad to promote skeletal muscle development thereby increasing muscle mass in livestock and obviating the need for excessive use of antibiotics and hormones to improve feed conversion and weight gain in animals. The methods can also be used in drug screening.

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L14: Entry 15 of 16 File: DWPI Dec 30, 2003

DERWENT-ACC-NO: 1998-008876
DERWENT-WEEK: 200402

TITLE: Production of inactivated bioactive poly:peptide(s), particularly neuro:toxin(s) - by expression of DNA encoding the polypeptide in such a way that one or more di:sulphide bridges are not formed

Basic Abstract Text (2):
USE - The methods can be used for producing BPs which are inactivated yet still retain other useful properties such as immunogenicity and/or antiviral, anti-tumour or wound healing activity. They can be used with toxins affecting the presynaptic neurojunction such as notexin, beta -bungarotoxin, crotoxin, taipoxin, textilotoxin and a-latrotoxin, toxins affecting the postsynaptic neurojunction such as a-conotoxins, a-cobrotoxin, erabutoxin, a-cobratoxin and a-bungarotoxin, toxins affecting ion channels such as dendrotoxins, scorpion toxins, m-conotoxins, and sea anemone toxins, or cell membrane-damaging toxins such as myotoxins, cardiotoxins, mellitin, and phospholipases. The inactivated neurotoxin composition can be used for the study and treatment of viral and neurological diseases.

Equivalent Abstract Text (2):
USE - The methods can be used for producing BPs which are inactivated yet still retain other useful properties such as immunogenicity and/or antiviral, anti-tumour or wound healing activity. They can be used with toxins affecting the presynaptic neurojunction such as notexin, beta -bungarotoxin, crotoxin, taipoxin, textilotoxin and a-latrotoxin, toxins affecting the postsynaptic neurojunction such as a-conotoxins, a-cobrotoxin, erabutoxin, a-cobratoxin and a-bungarotoxin, toxins affecting ion channels such as dendrotoxins, scorpion toxins, m-conotoxins, and sea anemone toxins, or cell membrane-damaging toxins such as myotoxins, cardiotoxins, mellitin, and phospholipases. The inactivated neurotoxin composition can be used for the study and treatment of viral and neurological diseases.

Equivalent Abstract Text (4):
USE - The methods can be used for producing BPs which are inactivated yet still retain other useful properties such as immunogenicity and/or antiviral, anti-tumour or wound healing activity. They can be used with toxins affecting the presynaptic neurojunction such as notexin, beta -bungarotoxin, crotoxin, taipoxin, textilotoxin and a-latrotoxin, toxins affecting the postsynaptic neurojunction such as a-conotoxins, a-cobrotoxin, erabutoxin, a-cobratoxin and a-bungarotoxin, toxins affecting ion channels such as dendrotoxins, scorpion toxins, m-conotoxins, and sea anemone toxins, or cell membrane-damaging toxins such as myotoxins, cardiotoxins, mellitin, and phospholipases. The inactivated neurotoxin composition can be used for the study and treatment of viral and neurological diseases.

Previous Doc Next Doc Go to Doc#

```
File 155:MEDLINE(R) 1951-2005/Aug W1
       (c) format only 2005 Dialog

      Set  Items  Description
      ---  -----  -----------
?

Ref   Items  Index-term
E1        3  DECUBITEX
E2        1  DECUBITEXMADRASSER
E3      116 *DECUBITI
E4        1  DECUBITII
E5       12  DECUBITIS
E6        2  DECUBITIUS
E7      126  DECUBITO
E8        1  DECUBITODEOXIA
E9        1  DECUBITORMADRASSEN
E10       2  DECUBITOS
E11       1  DECUBITOUS
E12       1  DECUBITUL

          Enter P or PAGE for more
?
? s e3-e6
              116  DECUBITI
                1  DECUBITII
               12  DECUBITIS
                2  DECUBITIUS
      S1      131  E3-E6
? e pressure sore

Ref   Items   RT  Index-term
E1    11194       PRESSURE    RESPIRATION   //POSITIVE   (POSITIVE-PRESSURE
                  RESPIRATION)
E2      167       PRESSURE RESPIRATION, INTRINSIC //POSITIVE (POSITIVE-PRE-
                  SSURE RESPIRATION, INTRINSIC)
E3        0    1 *PRESSURE SORE
E4        0    1  PRESSURE SUITS
E5        0    1  PRESSURE ULCER
E6     1671       PRESSURE      VENTILATION     //INTERMITTENT     POSITIVE
                  (INTERMITTENT POSITIVE-PRESSURE VENTILATION)
E7        1       PRESSUREA
E8        1       PRESSUREALGOMETER
E9        1       PRESSUREAND
E10       1       PRESSUREASE
E11       1       PRESSURECOOKER
E12       1       PRESSURECUP

          Enter P or PAGE for more
? e e3

Ref   Items Type  RT  Index-term
R1        0        1 *PRESSURE SORE
R2     6466   X    5  DECUBITUS ULCER
? s r1-r2
                0  PRESSURE SORE
             6466  DECUBITUS ULCER
      S2     6466  R1-R2
? e r2
```

```
Ref    Items Type  RT  Index-term
R1      6466         5 *DECUBITUS ULCER
R2      6344    X       DC=C17.800.893.289. (DECUBITUS ULCER)
R3        39    X    1  BEDSORE
R4         0    X    1  PRESSURE SORE
R5         0    X    1  PRESSURE ULCER
R6      4959    B    7  SKIN ULCER
? s r1:r7
      S3   11344  R1:R7
? e pressure ulcer

Ref    Items    RT  Index-term
E1         0     1  PRESSURE SORE
E2         0     1  PRESSURE SUITS
E3         0     1 *PRESSURE ULCER
E4      1671        PRESSURE      VENTILATION     //INTERMITTENT     POSITIVE
                    (INTERMITTENT POSITIVE-PRESSURE VENTILATION)
E5         1        PRESSUREA
E6         1        PRESSUREALGOMETER
E7         1        PRESSUREAND
E8         1        PRESSUREASE
E9         1        PRESSURECOOKER
E10        1        PRESSURECUP
E11      414        PRESSURED
E12        1        PRESSUREDETERMINATION

          Enter P or PAGE for more
? e e3

Ref    Items Type  RT  Index-term
R1         0         1 *PRESSURE ULCER
R2      6466    X    5  DECUBITUS ULCER
? ds

Set      Items   Description
S1         131   E3-E6
S2        6466   R1-R2
S3       11344   R1:R7
? s pressure? (2n) (ulcer? or sore? or bedsore?)
          615108  PRESSURE?
          152265  ULCER?
            8402  SORE?
             259  BEDSORE?
      S4    4061  PRESSURE? (2N) (ULCER? OR SORE? OR BEDSORE?)
? ds

Set      Items   Description
S1         131   E3-E6
S2        6466   R1-R2
S3       11344   R1:R7
S4        4061   PRESSURE? (2N) (ULCER? OR SORE? OR BEDSORE?)
? s (s1 or s2 or s3 or s4)
             131  S1
            6466  S2
           11344  S3
            4061  S4
      S5   12363  (S1 OR S2 OR S3 OR S4)
? e botulinum toxin
```

```
Ref    Items    RT  Index-term
E1        91       BOTULINUM ANTITOXIN --THERAPEUTIC USE --TU
E2         1       BOTULINUM ANTITOXIN --TOXICITY --TO
E3         0      *BOTULINUM TOXIN
E4      1832    4  BOTULINUM TOXIN TYPE A
E5       659       BOTULINUM TOXIN TYPE A --ADMINISTRATION AND DO
E6       268       BOTULINUM TOXIN TYPE A --ADVERSE EFFECTS --AE
E7        16       BOTULINUM TOXIN TYPE A --ANALYSIS --AN
E8        27       BOTULINUM TOXIN TYPE A --ANTAGONISTS AND INHIB
E9         8       BOTULINUM TOXIN TYPE A --BIOSYNTHESIS --BI
E10        5       BOTULINUM TOXIN TYPE A --BLOOD --BL
E11        3       BOTULINUM TOXIN TYPE A --CHEMICAL SYNTHESIS --
E12       65       BOTULINUM TOXIN TYPE A --CHEMISTRY --CH

          Enter P or PAGE for more
? s e4-e12
            1832  BOTULINUM TOXIN TYPE A
             659  BOTULINUM TOXIN TYPE A --ADMINISTRATION AND DO
             268  BOTULINUM TOXIN TYPE A --ADVERSE EFFECTS --AE
              16  BOTULINUM TOXIN TYPE A --ANALYSIS --AN
              27  BOTULINUM TOXIN TYPE A --ANTAGONISTS AND INHIB
               8  BOTULINUM TOXIN TYPE A --BIOSYNTHESIS --BI
               5  BOTULINUM TOXIN TYPE A --BLOOD --BL
               3  BOTULINUM TOXIN TYPE A --CHEMICAL SYNTHESIS --
              65  BOTULINUM TOXIN TYPE A --CHEMISTRY --CH
      S6    1832  E4-E12
? e e4

Ref    Items Type  RT  Index-term
R1      1832         4 *BOTULINUM TOXIN TYPE A
R2      1832   X       DC=D24.185.926.123.179.50. (BOTULINUM TOXIN TYPE A)
R3      1832   X       DC=D24.185.926.640.75.50. (BOTULINUM TOXIN TYPE A)
R4      4391   B   11  BOTULINUM TOXINS
R5      1337   B   34  NEUROMUSCULAR AGENTS
? p
>>>Related terms display completed...
? s r1:r4
      S7    6085  R1:R4
? e r4

Ref    Items Type  RT  Index-term
R1      4391        11 *BOTULINUM TOXINS
R2      4391   X       DC=D24.185.926.123.179. (BOTULINUM TOXINS)
R3      4391   X       DC=D24.185.926.640.75. (BOTULINUM TOXINS)
R4       172   X    1  BOTULIN
R5         0   X    1  CLOSTRIDIUM BOTULINUM TOXINS
R6      2409   R   10  BOTULISM
R7       940   R  109  CHOLINERGIC AGENTS
R8      1938   R   11  CLOSTRIDIUM BOTULINUM
R9       588   B   29  ANTI-DYSKINESIA AGENTS
R10    14496   B   17  BACTERIAL TOXINS
R11     9466   B   15  NEUROTOXINS
R12     1832   N    4  BOTULINUM TOXIN TYPE A
? p
>>>Related terms display completed...
? s r1:r12
      S8   32948  R1:R12
? s botulinolysin?
      S9       5  BOTULINOLYSIN?
? e botulinolysin
```

```
Ref    Items  Index-term
E1        12  BOTULINIUM
E2         2  BOTULINOGENIC
E3         5 *BOTULINOLYSIN
E4         4  BOTULINOPHILIA
E5         2  BOTULINOPHILIE
E6         1  BOTULINOPODOBNE
E7         8  BOTULINOVOGO
E8         1  BOTULINOVOI
E9         2  BOTULINOVOMU
E10        1  BOTULINOVUKH
E11        1  BOTULINOVYI
E12        3  BOTULINOVYKH

          Enter P or PAGE for more
? e botinolysin

Ref    Items  Index-term
E1         2  BOTING
E2         1  BOTINGER
E3         0 *BOTINOLYSIN
E4         1  BOTINYL
E5         1  BOTIQU
E6         1  BOTIQUAN
E7         6  BOTIQUIN
E8         2  BOTIQUINES
E9         1  BOTIT1
E10        1  BOTIT1 TOXIN
E11        5  BOTIT2
E12        4  BOTIT2 TOXIN

          Enter P or PAGE for more
? s e9-e12
               1  BOTIT1
               1  BOTIT1 TOXIN
               5  BOTIT2
               4  BOTIT2 TOXIN
     S10       6  E9-E12
? ds

Set     Items   Description
S1        131   E3-E6
S2       6466   R1-R2
S3      11344   R1:R7
S4       4061   PRESSURE? (2N) (ULCER? OR SORE? OR BEDSORE?)
S5      12363   (S1 OR S2 OR S3 OR S4)
S6       1832   E4-E12
S7       6085   R1:R4
S8      32948   R1:R12
S9          5   BOTULINOLYSIN?
S10         6   E9-E12
? s s5 and (s6 or s7 or s8 or s9 or s10)
           12363  S5
            1832  S6
            6085  S7
           32948  S8
               5  S9
               6  S10
     S11       4  S5 AND (S6 OR S7 OR S8 OR S9 OR S10)
```

? t s11/9/all

Search	Most Recent Queries	Time	Resu
#17	Search **botulinolysin sore**	10:43:37	
#16	Search **botulinolysin decubiti**	10:43:30	
#15	Search **botulinolysin**	10:43:15	
#14	Search **botinolysin**	10:43:09	
#11	Search **pressure sore botulinum**	10:42:50	
#13	Search **pressure sore botinolysin**	10:42:38	64
#12	Search **pressure sore botulin**	10:42:18	
#4	Search **Decubitus botulinum**	10:41:56	
#10	Search **decubitus botulinum**	10:41:43	
#9	Search **Decubiti botulinum**	10:41:33	
#8	Search **Decubiti botox**	10:41:28	
#7	Search **Decubitus neurotoxin**	10:41:19	
#6	Search **Decubitus botox**	10:41:03	
#3	Search **Decubitus**	10:40:33	81
#2	Search **decubiti**	10:40:19	64
#1	Search **decubidi**	10:40:15	